Quick search:
Content Ideas
Result Content Idea Research
Result Content Idea Research
1 Helsinn and MEI Discontinue Phase III Trial of Pracinostat in AML
2 Phase 3 Trial of Pracinostat Plus Azacitidine Combination in AML Discontinued
3 The end of the road beckons for pracinostat
4 Helsinn and MEI Pharma Announce Updated Clinical Data from the Phase 2 Study Evaluating Pracinostat in Combination with Azacitidine in Patients with High/Very-high Risk Myelodysplastic Syndromes
5 BRIEF-Helsinn Group And Mei Pharma Discontinue The Phase 3 Study With Pracinostat In Aml After Completing Interim Analysis
6 Helsinn and MEI Pharma Announce Publication of Phase II Data for Pracinostat in Combination with Azacitidine in Blood Advances
7 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in MEI Pharma, Inc. of Class Action Lawsuit and Upcoming Deadline – MEIP
8 Helsinn signs exclusive distribution and license agreements with Blanver and Varifarma for Pracinostat in South America
9 Helsinn and Endo Announce Agreement for Paladin Labs Inc. to Commercialize Pracinostat in Canada
10 Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat
11 Shareholder Alert: Robbins LLP Announces MEI Pharma, Inc. (MEIP) Accused of Misleading Shareholders
12 MEI Pharma: Give It Another Chance
13 BRIEF-Helsinn And MEI Pharma Announce Updated Clinical Data From Phase 2 Study Evaluating Pracinostat In Combination With Azacitidine
14 MEI Pharma
15 Bragar Eagel & Squire, PC Reminds Investors That Class Action Lawsuits Have Been Filed Against MEI Pharma, Cabot Oil & Gas, Kodak, and Genius Brands and Encourages Investors to Contact the Firm
16 MEI PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of MEI Pharma, Inc.
17 DEADLINE ALERT: Bragar Eagel & Squire, PC Reminds Investors That a Class Action Lawsuit Has Been Filed Against MEI Pharma, Inc. and Encourages Investors to Contact the Firm
18 Portnoy Law: Lawsuit Filed On Behalf of MEI Pharma, Inc. Investors
19 FDA Grants Pracinostat Breakthrough Designation for AML
20 Constellation Pharma: CPI-0610 Is Well-Differentiated In The Myelofibrosis Treatment Development Pipeline
21 Pomerantz Law Firm Announces the Filing of a Class Action against MEI Pharma, Inc. and Certain Officers
22 Why MEI Pharma's Stock Is Trading Higher Today
23 Global Thrombocythaemia Myelofibrosis Treatment market 2020 ? 2027 analysis examined in new market research report
24 ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Reminds MEI Pharma, Inc. Investors of the Important Deadline in Securities Class Action – MEIP
25 MEIP SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies MEI Pharma, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
26 Menarini Ricerche Announces Initiation of Cohort Expansion for the Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia
27 25th EHA Congress: Menarini Ricerche Discloses First Results From the Clinical Study on SEL24/MEN1703
28 Menarini bags blood cancer drug with $677M Stemline acquisition
29 Oral AML Therapy Onureg Gets FDA Approval
30 MEI Pharma (MEIP) Reports Positive Phase II Results for Pracinostat Combo With Azacitidine in AML
31 Menarini Announces Results from New Preclinical Studies on MEN1611 for the Treatment of Breast Cancer at the 2020 San Antonio Breast Cancer Symposium
32 Pemmaraju Reviews Potential Combination Regimens With Ruxolitinib for Myelofibrosis
33 MEI Pharma Set To Explode With Announcement Of Lucrative Partnership
34 Global Acute Myeloid Leukemia (AML) Disease Analysis Report 2020
35 MEI Pharma (MEIP) to Report Q4 Earnings: What's in the Cards?
36 MEI Pharma (MEIP), Helsinn Group Dose First Patient in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in MDS
37 MEI Pharma: Best-In-Class P13K Delta Inhibitor Makes Significant Progress In The Clinic
38 MEI Pharma Shares Rise 50% on $682.5M Partnership with Japanese Company to Treat B-cell Malignancies
39 Roche and Celgene set for battle in acute myelogenous leukaemia
40 MEIP INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies MEI Pharma, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
41 Global Essential Thrombocythemia Drug Market Outlook 2020-2026 : Aop Orphan Pharmaceuticals AG, Italfarmaco SpA, PharmaEssentia Corp
42 MEI Pharma Reports Second Quarter Fiscal Year 2017 Results
43 Venetoclax regimen extends OS in AML subset
44 Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus
45 5 Top Stocks That Have Skyrocketed in the Past 7 Days
46 MEI Pharma (MEIP) Presents At 16th Annual Needham Healthcare Conference
47 MEI Pharma and Kyowa Hakko Kirin Announce License Agreement to Develop and Commercialize ME-401 in Japan
48 Path to a targeted treatment for small-cell lung cancer?
49 FDA Grants Full Approval to Venclexta for Acute Myeloid Leukemia
50 Menarini Ricerche Announces SEL24/MEN1703 Pharmacodynamic Data from the Dose Escalation Part of DIAMOND-01 Trial
51 Novel Targets Outside of JAK Inhibition Inching into Myelofibrosis Treatment Landscape
52 US FDA Approves Venetoclax for the Treatment of Acute Myeloid Leukemia
53 SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of MEI Pharma, Inc.
54 VIALE-A Study Showed Venetoclax + Azacitidine Reduced Risk of Death in Newly-diagnosed AML
55 Menarini Ricerche Announces Dose Escalation Results of the Clinical Trial of MEN1611 in Breast Cancer
56 Current State of Myelodysplastic Syndromes: Standard Treatment Practices and Therapeutic Advances
57 Lifshitz Law Firm, PC Announces Investigation of Cognizant Technology Solutions Corporation, Honeywell International Inc., MEI Pharma, Inc., Nikola Corporation, The Chemours Company and YayYo, Inc.
58 Cryogenic Tank Manufacturer Hit With 70 Lawsuits After Product Failure in San Francisco Fertility Clinic | The Recorder
59 Lawyers for Thernaos' Elizabeth Holmes Ask to Push Back Trial Until April Amid COVID-19 Concerns | The Recorder
60 MEI Pharma Announces Updated Clinical Data from ME-401 Phase 1b Study in Patients with Indolent B-cell Malignancies
61 'Complex Is a Term of Art': Theranos Judge Indicates Additional Charges Were Expected | The Recorder
62 Lawyers Lash Becerra Over Move to Restrict New Opioid Suits | The Recorder
63 San Francisco US Attorney Names No. 2, Launches Securities Fraud Section | The Recorder
64 Amodiaquine, zuclopenthixol and nebivolol can help treat COVID-19, finds new study
65 Nevro, Morrison & Foerster Win Appeal Over Spinal Stimulation Patents | The Recorder
66 Putting the brakes on small cell lung carcinoma
67 Penny Stocks On Robinhood To Watch During The Holidays
68 BitClave to Refund Investors $25.5M in SEC Settlement | The Recorder
69 Lawyers for Elizabeth Holmes Urge Pushback of August Trial Date, Prosecutors Endorse October Start | The Recorder
70 MEIP EQUITY NOTICE: ROSEN, A NATIONAL INVESTOR LAW FIRM, Encourages MEI Pharma, Inc. Investors with Losses to Contact Firm Before Important Deadline in Securities Class Action – MEIP
71 MEI Pharma and BeiGene Announce Clinical Collaboration to Evaluate ME-401 in Combination with Zanubrutinib in Patients with B-Cell Malignancies
72 MEI Pharma licenses ME-401 to Kyowa Hakko Kirin in Japan
73 Shareholder Suit Filed Over Intel's Handling of Manufacturing Delay | Delaware Business Court Insider
74 MEI Pharma Acquires PWT143, A Highly Selective PI3-Kinase Delta Inhibitor
75 Cannabis in the Classroom: Navigating the Administration of Medical Marijuana on Campus Under New California Law | The Recorder
76 The SEC May Lose Again in the Supreme Court in 'Liu v. SEC' | The Recorder
77 Facebook Shareholders Can't Bypass Board to Pursue $90M Case | Delaware Business Court Insider
78 Tracon’s latest oncology failure leaves little to excite investors
79 Investors feel the pain of HLB’s interest in biotech
80 MEIP, COG & KODK Investor Alert: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Upcoming Lead Plaintiff Deadlines
81 In Del. Case, Shareholder Says Advance Auto Parts Executives Concealed Supply Failings | Delaware Business Court Insider
82 Current and Emerging Therapies for Patients With Acute Myeloid Leukemia: A Focus on MCL-1 and the CDK9 Pathways
83 MEI Pharma Completes Public Offering of Common Stock
84 Ignyta Is Proof That Biotech Bargains Still Exist
85 MEI Pharma Announces Topline Data From Phase I Clinical Trial Of Mitochondrial Inhibitor Drug Candidate ME-344
86 MF and PV Diagnosis, Stratification, and Management Depend on Molecular and Clinical Characterizations
87 First-line atezolizumab improves PFS for advanced squamous non-small cell lung cancer
88 Maintenance chemotherapy improves OS in rhabdomyosarcoma
89 Raising standards and access across Latin America means close collaboration, says FIFARMA's Rafael Diaz-Granados
90 What drugmakers should consider when accessing the Latin American market
91 Mental Health Care Providers Seek Payment From UnitedHealthcare for Billions in 'Wrongfully Denied Claims' | The Recorder
92 Menarini Ricerche at the ASCO Annual Meeting 2019 With Three Different Projects in Oncology
93 Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro
94 MoFo Hires SEC Vet Jina Choi, Former Head of SF Regional Office | The Recorder
95 Learn How To Invest Against Acute Myeloid Leukemia, One Of The Fastest-Growing Cancer Markets
96 Global Acute Myeloid Leukemia (AML) Therapeutics
97 Latin America's pharma industry staying optimistic despite economic uncertainty
98 Novel Securities Case Against Theranos Stumbles Over 'Reliance' Issues | The Recorder
99 What Does Breakthrough Therapy Designation Really Mean For My Company?
100 5 Sizzling Stocks Trading Under $10 With Gigantic Upside Potential